Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery;Análisis coste-efectividad de la cirugía del glioma maligno guiada por fluorescencia con ácido 5-aminolevulínico

Neurologia

Volumn 30, Issue 3, 2015, Pages 163-168

  Slof, J ^a   Diez Valle R ^b   Galvan J ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Gebro Pharma Ltd   (Spain)

Author keywords

5 aminolevulinic acid; Cost effectiveness; Fluorescence guided surgery; Glioblastoma; Malignant glioma

Indexed keywords

AMINOLEVULINIC ACID;

ARTICLE; CANCER SURGERY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE; GLIOBLASTOMA; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SPAIN; WHITE LIGHT; ADULT; AGED; BRAIN NEOPLASMS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; GLIOMA; HUMAN; MALE; MIDDLE AGED; NEUROSURGERY; PATHOLOGY;

ADULT; AGED; AMINOLEVULINIC ACID; BRAIN NEOPLASMS; COST-BENEFIT ANALYSIS; FLUORESCENCE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; QUALITY-ADJUSTED LIFE YEARS; SPAIN;

EID: 84925166510     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2013.11.002     Document Type: Article

References (17)

1. Ostrom Q.T., Gittleman H., Farah P., Ondracek A., Chen Y., Wolinsky Y., et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro Oncol 2013, 15(Suppl 2):ii1-ii56.
2. Laws E.R., Parney I.F., Huang W., Anderson F., Morris A.M., Asher A., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. Neurosurg 2003, 99:467-473.
3. Helseth R., Helseth E., Johannesen T.B., Langberg C.W., Lote K., Rønning P., et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010, 122:159-167.
4. Stupp R., Pavlidis N., Jelic S. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 2005, 16(Suppl 1):i64-i65. for the ESMO Guidelines Task Force.
5. Stummer W., Kamp A. The importance of surgical resection in malignant glioma. Curr Opin Neurol 2009, 22:645-649.
6. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. Fluorescence-guided surgery with 5-aminovulinic acid for resection of malignant glioma: A randomised controlled phase III trial. Lancet Oncol 2006, 7:392-401.
7. Stummer W., Reulen H.J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C., et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 2008, 62:564-576.
8. Sanai N., Polley M.Y., McDermott M.W., Parsa A.T., Berger M.S. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011, 115:3-8.
9. Lacroix M., Abi-Said D., Fourney D.R., Gokaslan Z.L., Shi W., DeMonte F., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198.
10. Gil-Salú J.L., Arraez M.A., Barcia J.A., Piquer J., Rodríguez de Lope A., Villalba Martínez G. Recomendaciones sobre el uso de ácido 5-aminolevulínico en la cirugía de los gliomas malignos. Documento de consenso. Neurocirugía 2013, 24:163-171.
11. Rogers G., Garside R., Mealing S., Pitt M., Anderson R., Dyer M., et al. Carmustine implants for the treatment of newly diagnosed high-grade gliomas. PharmacoEconomics 2008, 26:33-44.
12. Diez Valle R., Slof J., Galván J., Arza C., Romariz C., Vidal C. Estudio observacional retrospectivo sobre la efectividad del ácido 5-aminolevulínico en el tratamiento de los gliomas malignos en España (Estudio VISIONA). Neurologia 2013, 10.1016/j.nrl.2013.05.004.
13. Dolan P. Output measures and valuation in health. Economic evaluation in healthcare: Merging theory with practice 2001, Oxford University Press, New York. M. Drummond, A. McGuire (Eds.).
14. Orden SSI/2687/2012, de 17 de diciembre, por la que se actualizan los anexos i, ii y iii del Real Decreto 1207/2006, de 20 de octubre, por el que se regula la gestión del Fondo de cohesión sanitaria.
15. De Cock E., Miratvilles M., González-Juanatey J.R., Azanza-Perea J.R. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. Pharmacoeconomics Sp Res Art 2007, 4:97-107.
16. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
17. Latimer N.R. Survival analysis for economic evaluations alongside clinical trials -extrapolation with patient-level data: Inconsistencies, limitations, and a practical guide. Med Decis Making 2013, 33:743-754.